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ABSTRACT 
Background: To investigate the diagnostic value of perfusion 99mTc-exametazime single 
photon emission computed tomography (SPECT) in the diagnosis of dementia with Lewy 
bodies (DLB) and Alzheimer’s disease (AD) in comparison with dopaminergic 123I-2β-
carbomethoxy-3β-(4-iodophenyl)-n-(3-fluoropropyl) nortropane (FP-CIT) SPECT 
imaging. 
Methods: Subjects underwent 99mTc-exametazime (39 controls, 36 AD, 30 DLB) and 
123I-FP-CIT (33 controls, 33 AD, 28 DLB) scanning. For each scan, 5 raters performed 
visual assessments blind to clinical diagnosis on selected transverse 99mTc-exametazime 
images in standard stereotactic space. Diagnostic accuracy of 99mTc-exametazime was 
compared to 123I-FP-CIT results for the clinically relevant subgroups AD and DLB using 
receiver operating characteristic (ROC) curve analysis. 
Results: Inter-rater agreement for categorising uptake was ‘moderate’ (mean kappa = 
0.53) for 99mTc-exametazime and ‘excellent’ (mean kappa = 0.88) for 123I-FP-CIT. For 
AD and DLB, consensus rating matched clinical diagnosis in 56% of cases using 99mTc-
exametazime and 84% using 123I-FP-CIT. In distinguishing AD from DLB, ROC analysis 
revealed superior diagnostic accuracy with 123I-FP-CIT (ROC curve area 0.83, sensitivity 
78.6%, specificity 87.9%) compared to occipital 99mTc-exametazime (ROC curve area 
0.64, sensitivity 64.3%, specificity 63.6%) p=0.03. 
Conclusion: Diagnostic accuracy was superior with 123I-FP-CIT compared to 99mTc-
exametazime in the differentiation of DLB from AD.  
 
Keywords: Neuroimaging; Visual Rating; Region of Interest; ROC; Perfusion; Dopamine 
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Introduction  
Dementia with Lewy bodies (DLB) is the second most common cause of degenerative 
dementia after Alzheimer’s disease (AD), accounting for 15-20% of cases in older 
people. Clinically it is characterised by attentional fluctuation, recurrent visual 
hallucinations and motor features of parkinsonism, while histopathologically by cortical 
and sub-cortical Lewy bodies (McKeith et al., 1996). However, due to overlapping 
clinical features and low sensitivity of clinical diagnostic criteria, the differential 
diagnosis of AD and DLB remains a major problem in clinical practice (McKeith et al., 
1994). Accurate detection of DLB is important because of management implications 
including different prognosis, adverse sensitivity to neuroleptic agents (Aarsland et al., 
2005) and positive response of behavioural features to cholinesterase inhibitors (Aarsland 
et al., 2004). Investigations which could help improve the accuracy of discrimination 
between DLB and AD would be a major advance.  
 
Numerous studies of cerebral metabolic imaging using positron emission tomography 
(PET) (Gilman et al., 2005; Ishii et al., 1998; Minoshima et al., 2001), and cerebral 
perfusion imaging using single photon emission computed tomography (SPECT) 
(Lobotesis et al., 2001; Pasquier et al., 2002; Shimizu et al., 2005), have suggested that 
occipital deficits are a distinctive feature of DLB. Other PET and SPECT tracers, namely 
18F-fluoro-L-dopa (F-DOPA), 123I-2-beta-carbomethoxy-3-beta-4-fluorophenyl-tropane 
(β-CIT) and 123I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane 
(FP-CIT), which were developed to evaluate various aspects of dopaminergic function, 
have demonstrated utility in differentiating AD from DLB (Ceravolo et al., 2003; O'Brien 
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et al., 2004; Walker et al., 2002). In addition, some studies have utilised 123I-
metaiodobenzylguanidine (MIBG) SPECT myocardial scintigraphy, which detects early 
disturbances of the sympathetic nervous system, and have shown promising results in 
distinguishing DLB from AD (Hanyu et al., 2006a; Oide et al., 2003). Most PET and 
SPECT uptake studies in AD and DLB have involved group comparisons, whereas fewer 
studies have investigated the value of imaging when applied to diagnosis of individual 
cases. Of these studies results have been variable, with some suggesting occipital 
hypoperfusion is relatively effective (sensitivity 74% - 85%) in diagnosing DLB (Hanyu 
et al., 2006a; Hanyu et al., 2006b; Shimizu et al., 2005), while others have revealed less 
accuracy (sensitivity 65%) (Lobotesis et al., 2001; Pasquier et al., 2002), including one 
study that showed that reduced occipital perfusion on visual inspection was indeterminate 
for a diagnosis of DLB (Kemp et al., 2007). There have been few studies comparing 
diagnostic accuracy between different techniques in the same subjects, and no 
comparisons of FP-CIT and perfusion SPECT. 
 
In the present study, the aim was to investigate the use of perfusion 99mTc-exametazime 
SPECT in the classification of normal elderly controls and patients with AD and DLB in 
accordance with clinical diagnosis as the gold standard. In particular, we wanted to 
compare the diagnostic accuracy of occipital lobe hypoperfusion with previous 
dopaminergic 123I-FP-CIT (DaTSCAN) imaging data in the clinically relevant differential 
diagnosis of AD and DLB.    
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Methods 
Subjects 
The study population consisted of 105 subjects (39 elderly controls, 36 AD, 30 DLB). 
Patients were recruited from a community-dwelling population who had been referred to 
local old age psychiatry services. Elderly controls were recruited from friends and 
spouses of patients included in this and other local research studies. The study was 
approved by the local research ethics committee and UK Department of Health’s 
Administration of Radioactive Substances Advisory Committee (ARSAC). All 
participants, as well as the nearest relative for patients, gave informed written consent. 
 
Subjects underwent detailed physical, neurological and neuropsychiatric examinations, 
which included history, mental state and physical examination. This comprised routine 
haematology and biochemistry screening, thyroid function tests, syphilis serology, 
vitamin B12 and folate levels, chest X-ray and head CT scan. Other tests included the 
Mini-Mental State Examination (MMSE) (Folstein et al., 1975) and the Cambridge 
Cognitive Examination (CAMCOG) (Roth et al., 1986), while parkinsonism was rated 
using the motor subsection of the Unified Parkinson’s Disease Rating Scale (UPDRS III) 
(Fahn et al., 1987). Patient diagnosis was carried out by agreement between two 
experienced consultant old age psychiatrists using the NINCDS-ADRDA criteria for AD 
(McKhann et al., 1984), and the international workshop criteria for DLB (McKeith et al., 
1996). For AD, 33 patients were diagnosed as ‘probable’ and 3 patients as ‘possible’ 
while for DLB, 23 patients were diagnosed as ‘probable’ and 7 patients as ‘possible’. 
Controls had no signs or symptoms of cognitive disturbance, did not complain of poor 
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memory and all scored within normal range of cognitive tests (≥ 25 on MMSE and ≥ 85 
on CAMCOG). Subsequently all subjects underwent SPECT scanning. 
 
99mTc-exametazime and 123I-FP-CIT (DaTSCAN) SPECT imaging 
All subjects were scanned using a triple-headed rotating gamma camera (Picker 3000XP) 
fitted with a high resolution fan-beam collimator, approximately 10 minutes after a bolus 
intravenous injection of 500 MBq of 99mTc-exametazime (Ceretec, GE Healthcare, also 
referred to as HMPAO). One hundred and twenty 15 second views over a 360° orbit were 
acquired on a 128×128 matrix with a pixel and slice thickness of 3.5mm. Imaging time 
was 30 minutes. Images were reconstructed using ramp-filtered backprojection with a 
Butterworth filter (order 13, cut-off 0.2 cycles.cm-1), then resampled to a 64×64 matrix 
containing 4.0mm cubic voxels. Axial resolution was 12mm full width at half maximum 
(FWHM) and the reconstructed images were corrected for gamma ray attenuation using 
Chang’s algorithm (uniform attenuation coefficient, µ = 0.11cm-1).  
 
Within 3 months of their 99mTc-exametazime scan; most patients (Controls (n=33), AD 
(n=33), DLB (n=28)) underwent 123I-FP-CIT (DaTSCAN, GE Healthcare, UK) SPECT 
scanning. Acquisition and processing of scans have been previously described (O'Brien et 
al., 2004). 
 
Pre-processing of 99mTc-exametazime scans 
First, in order that all SPECT scans be visually rated from equivalent slices, each image 
volume was registered to match a 99mTc-exametazime SPECT template in standard MNI 
Differential diagnosis of AD and DLB 
 7
(Montreal Neurological Institute, http://www.bic.mni.mcgill.ca) space using statistical 
parametric mapping (SPM2, Wellcome Department of Imaging Neuroscience, London, 
UK, http://www.fil.ion.ucl.ac.uk/spm). The template was constructed from 39 elderly 
controls (all of whom participated in this study) by spatial normalisation of each scan to 
the generic SPM2 SPECT template. The transformed images were then visually inspected 
to ensure registration to the template was successful, and a mean image was created from 
the registered scans followed by spatial smoothing with an 8mm FWHM 3D Gaussian 
filter. Next, using the freeware medical image viewer ‘MRIcro’ 
(http://www.sph.sc.edu/comd/rorden/mricro.html) and Talairach atlas (Talairach and 
Tournoux, 1988), 12 transverse images as well as a single coronal slice in standard space 
were selected for visual rating. Images were displayed relative to their maximum voxel 
count. Figure 1 shows the MRIcro display of the 99mTc-exametazime SPECT template 
together with the neuroanatomical landmarks of each slice and colour scale used for 
visual rating.  
 
Visual rating of 99mTc-exametazime scans  
Visual qualitative assessment of scans were carried out simultaneously by 5 raters of 
varying experience (low to high), comprising of 2 consultant medical physicists, a 
consultant old age psychiatrist and 2 imaging research associates. All registered scans 
were independently randomised and rated blind to clinical diagnosis. All images were 
displayed using MRIcro on a PC and projected onto a large screen in full view of the 
rating panel (approximate dimensions: screen size (w x h) 1.8m x 1.35m, screen to panel 
distance 3.0m). Initially a brief training exercise was performed by the panel on 10 
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randomly selected images; these allowed raters to discuss uptake patterns of scans and 
gain experience implementing the study protocol (see below). 
 
For each scan, 4 brain regions i.e., medial temporal/temporal, occipital, parietal and 
midline parietal (representing cuneus, precuneus, posterior cingulate) were assessed and 
rated by each panel member. These regions were chosen on the basis of past research 
suggesting greatest changes in DLB occur in occipital and precuneal areas (Firbank et al., 
2003; Ishii et al., 1999b; Lobotesis et al., 2001; Pasquier et al., 2002), while changes in 
AD are most pronounced in temporal and parietal areas (Imran et al., 1999; Ishii et al., 
1999a; Lee et al., 2003; Lobotesis et al., 2001). Rating scores used a dichotomous 
variable (0 = normal uptake, 1 = reduced uptake) based on the pattern of uptake. Each 
rater additionally classified every scan as either a control, AD or DLB. Guidelines for 
diagnosis were: 
 
• CONTROL = global uptake broadly normal, however could contain minor focal 
deficits. 
• AD = reduced uptake and confined largely to temporal, medial temporal, parietal 
and posterior cingulate regions. 
• DLB = reduced uptake and confined largely to occipital, parietal, cuneal and 
precuneal regions.  
 
Following visual rating, consensus measures (obtained from majority results) were 
determined for each region in addition to a consensus diagnosis. 
Differential diagnosis of AD and DLB 
 9
Visual rating of 123I-FP-CIT scans 
Visual inspection was performed by 5 raters, two of whom participated in the rating of 
99mTc-exametazime scans. A detailed description of the methodology has been previously 
reported (O'Brien et al., 2004). Briefly, visual rating used the 4-category grading system 
for 123I-FP-CIT tracer uptake according to the classification initially proposed by 
Benamer et al (Benamer et al., 2000): 
 
• Normal, grade 0: Tracer uptake bilateral in caudate nucleus and putamen and 
largely symmetric. 
• Abnormal, grade 1: Asymmetric uptake with normal or almost normal putamen 
activity in one hemisphere and with a more marked reduction in the contralateral 
putamen. 
• Abnormal, grade 2: Significant bilateral reduction in putamen uptake with activity 
confined to the caudate nuclei. 
• Abnormal, grade 3: Significant bilateral reduction in uptake affecting both the 
caudate nuclei and putamen. 
 
For the present study consensus scores were used and then reclassified as either normal or 
abnormal, i.e., (grade 0 = normal; grade 1, 2 and 3 = abnormal). The scores were then 
used to compare the diagnostic utility with 99mTc-exametazime. Figure 2 illustrates 
transverse views of typical ‘normal’ (A) and ‘abnormal’ (B) 123I-FP-CIT scans. 
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Statistical analyses 
Data were analysed using the Statistical Package for Social Sciences software (SPSS 
version 15.0). Continuous variables were tested for normality of distribution using the 
Shapiro-Wilk test and visual inspection of variable histograms. As a result, group effects 
were investigated using one-way analysis of variance ANOVA (F-test). Nominal data 
(consensus variables, gender) were summarised using cross-tabulation and evaluated for 
group differences where appropriate with χ2 tests. Inter-observer agreement between 
raters was assessed using Cohen’s kappa (κ) test. Sensitivity and specificity of 99mTc-
exametazime SPECT in distinguishing AD and DLB was determined from receiver 
operating characteristic (ROC) curve analysis (Zweig and Campbell, 1993). All statistical 
tests were reported as significant if p≤ 0.05.  
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Results  
Subject demographics 
Table 1 shows demographic and clinical characteristics of the study population. Groups 
were matched for sex (χ2= 1.8, df= 2, p= 0.4) and broadly matched for age (F2, 102= 3.1, 
p= 0.05), although AD were slightly older than controls (p= 0.05). Disease duration was 
similar between dementia groups (F1,56= 2.6, p= 0.11). As expected, significant 
differences were observed between patients and controls in MMSE (F2, 102= 87.0, 
p<<0.001) and CAMCOG (F2, 102= 96.8, p<<0.001), and between DLB and other groups 
in UPDRS III (F2, 102= 80.6, p<<0.001) scores. MMSE and CAMCOG results were 
comparable in AD and DLB. Some patients were receiving medication (for > 3months) at 
the time of their SPECT scans (AD: donepezil (n = 7), rivastigmine (n = 2); DLB: 
donepezil (n = 9), L-Dopa (n = 3)). 
 
Visual rating of 99mTc-exametazime and 123I-FP-CIT scans  
In each brain region, inter-rater agreement for 99mTc-exametazime was calculated from 
the mean kappa score of all pairwise combinations of the 5 panel members. Temporal, 
occipital, parietal and midline parietal scores were (κ ± standard error) 0.53 ± 0.08, 0.55 
± 0.08, 0.63 ± 0.08 and 0.49 ± 0.09 respectively. Global inter-rater agreement (mean of 
regional kappa scores) was 0.55 ± 0.08, demonstrating an overall ‘moderate’ concordance 
between raters in classifying abnormal and normal patterns of regional uptake. Likewise, 
agreement between raters in categorising the diagnosis of a case was also ‘moderate’ 
(0.51 ± 0.07). 
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Table 2 displays a summary of the 99mTc-exametazime visual rating results, where 
findings represent consensus variables. In controls, highest incidence of abnormal uptake 
occurred in temporal and parietal regions (21%), while the lowest was in midline parietal 
(10%). Figure 3a shows a typical MRIcro display of a 99mTc-exametazime scan of a 
control with its relatively well preserved perfusion throughout the cerebrum. In AD, 
abnormal uptake appeared mostly in temporal (86%) and parietal (69%) areas, and was 
least frequent in occipital and midline parietal (33%). Figure 3b illustrates a 
representative blood flow image of an AD patient. In DLB, incidence of abnormal uptake 
was 80% (parietal), 63% (occipital) and 57% (temporal, midline parietal). Figure 3c 
shows an example of the 99mTc-exametazime uptake pattern in DLB. Consensus 
diagnosis from visual rating matched clinical diagnosis in 65% (67/105) of cases. 
Proportion of correct diagnoses were greatest in controls (77%), followed by DLB (60%) 
then AD (53%). Complete diagnostic agreement between all 5 raters occurred in 40% of 
cases. 
 
Inter-rater agreement of 123I-FP-CIT was calculated from mean kappa scores of all 
pairwise combinations of panel members and was based on the 4-category grading 
system (O'Brien et al., 2004). The multi-rater kappa statistic was 0.88±0.02, indicating 
‘excellent’ global agreement between raters in classifying normal and abnormal patterns. 
Table 2 shows the 123I-FP-CIT results, where the highest frequency of abnormal uptake 
occurred in DLB (79%), followed by AD (12%) then controls (6%).  
 
 
 
Differential diagnosis of AD and DLB 
 13
ROC curve analysis 
 
Excluding controls, ROC curve analysis was used to assess the diagnostic performance of 
99mTc-exametazime by region in distinguishing DLB from AD (DLB=30, AD=36). In 
addition, diagnostic accuracy was assessed for dopaminergic 123I-FP-CIT in 
differentiating DLB from AD and then compared to the optimum 99mTc-exametazime 
method for cases who had undergone both investigations (DLB=28, AD=33). Table 3 
summarises for each diagnostic test the ROC curve area, optimal sensitivity and 
specificity, as well as positive and negative likelihood ratios. Diagnostic characteristics 
(ROC curve area, sensitivity, specificity) for each 99mTc-exametazime region produced 
the following range (min – max) of diagnostic values (0.55 - 0.65, 56.7% - 86.1%, 30.6% 
- 66.7%), indicating ‘poor’ precision when using individual regions as diagnostic 
markers. For 123I-FP-CIT, greater diagnostic accuracy was achieved in discriminating 
DLB from AD (0.83 ± 0.05, 78.6%, 87.9%). The most accurate 99mTc-exametazime 
region for differentiating DLB from AD was in the occipital lobe (0.65 ± 0.07, 63.3%, 
66.7%). Figure 4 shows ROC curves for both 123I-FP-CIT and occipital 99mTc-
exametazime, where significant differences were apparent between their ROC curve 
areas (~ 0.19 ± 0.09, p = 0.03), demonstrating the superior diagnostic ability of 123I-FP-
CIT over 99mTc-exametazime. In diagnosing AD and DLB assuming clinical diagnosis as 
the gold standard, prediction success using 99mTc-exametazime in AD and DLB were 
53% and 60% respectively, but using 123I-FP-CIT increased to 88% and 79%.  
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Autopsies 
Autopsy results were available for 9 patients (2 AD, 7 DLB). Table 4 shows selected 
99mTc-exametazime and 123I-FP-CIT SPECT imaging characteristics of the 9 autopsy 
confirmed cases. Clinical diagnosis agreed with autopsy diagnosis in all but one (case 8), 
highlighting the strength of clinical diagnostic criteria as rigorously applied in this study. 
123I-FP-CIT imaging agreed with autopsy diagnosis in 7/8 cases (88%). Consensus 99mTc-
exametazime visual rating was less accurate and agreed with autopsy diagnosis in 4/9 
cases (44%). Lastly, in light of the autopsy data, where 1 case changed diagnosis, data 
were reanalysed but results reported above were essentially unchanged.  
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Discussion 
We investigated visual inspection of 99mTc-exametazime SPECT imaging in the 
differentiation of AD, DLB and age-matched controls. Inter rater agreement was 
‘moderate’ for the evaluation of regional uptake and designation of likely diagnosis based 
on the imaging findings. Reduced overall uptake was found comparing dementia subjects 
to controls; in occipital and parietal regions when comparing DLB to AD; and reduced 
medial temporal uptake when comparing AD to DLB. Consensus imaging diagnosis 
matched clinical diagnosis in 65% of cases, and was highest in controls (77%), followed 
by DLB (60%) and AD (53%) groups. The results indicate that a large degree of overlap 
exists between patient groups in regional uptake patterns and points to the challenge in 
accurate visual inspection of 99mTc-exametazime SPECT scans in the assessment of 
dementia.  
 
The diagnostic value of 99mTc-exametazime SPECT by region in classifying subjects 
from the clinically relevant subgroups AD and DLB was performed by ROC curve 
analysis. Furthermore, diagnostic accuracy of the optimal 99mTc-exametazime method 
was directly compared to dopaminergic 123I-FP-CIT. The sensitivity and specificity of 
occipital 99mTc-exametazime SPECT was 64.3% and 63.6% respectively, demonstrating 
modest diagnostic utility. 123I-FP-CIT showed greater diagnostic accuracy (sensitivity 
78.6%, specificity 87.9%) than 99mTc-exametazime imaging in distinguishing DLB from 
AD. Inter-rater agreement was also superior for 123I-FP-CIT (mean κ = 0.88) (O'Brien et 
al., 2004; Walker et al., 2002), than with 99mTc-exametazime (κ = 0.55). This may reflect 
the fact that as distribution of 123I-FP-CIT is confined to basal ganglia its visual 
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interpretation is relatively straightforward after a brief period of training, whereas 99mTc-
exametazime and similar perfusion tracers are taken up throughout the brain and the 
rating of multiple regions may require significantly more expertise. 
 
Numerous cerebral perfusion SPECT imaging studies have investigated the diagnostic 
utility of differentiating between DLB and AD using occipital uptake measures as the 
discriminatory variable. The analyses showed a range of sensitivities and specificities of 
65-85% and 71-87% respectively (Hanyu et al., 2006a; Hanyu et al., 2006b; Lobotesis et 
al., 2001; Pasquier et al., 2002; Shimizu et al., 2005). One study by Hanyu et al, showed 
that diagnostic accuracy improved using combined MMSE and SPECT measures, where 
sensitivity increased from 75% to 81% and specificity from 78% to 85% (Hanyu et al., 
2006b). The results appear to be better than results reported from the present study 
(sensitivity 60.7%, specificity 81.8%). It may be that sensitivity improves when using 
quantitative rather than qualitative measures associated with visual methods. Studies 
using 18F-fluorodeoxyglucose (FDG) PET have generally shown greater precision than 
perfusion SPECT in distinguishing DLB from AD (Ishii et al., 1998; Minoshima et al., 
2001). Sensitivity and specificity are quoted as ranging from 86% to 92% and 80% to 
92% respectively; although such findings should be treated as tentative due to small 
sample sizes in these studies. A larger PET study by Gilman et al was less accurate 
(sensitivity 64%, specificity 65%), however specificity in excluding DLB increased from 
65% to 74% with the introduction of MMSE and motor scores (Gilman et al., 2005).    
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There is now increasing evidence that 123I-FP-CIT SPECT imaging can make a 
significant contribution to increasing the diagnostic accuracy of DLB. Walker et al 
revealed that an abnormal scan was associated with an autopsy diagnosis of DLB with a 
sensitivity of 88% and specificity of 100% (Walker et al., 2007). O’Brien et al using 
visual inspection reported a sensitivity of 78% and specificity of 85% in diagnosing ante-
mortem cases of DLB from AD (O'Brien et al., 2004). More recently, a large multicentre 
study was carried out to investigate the sensitivity and specificity in the ante-mortem 
differentiation of probable DLB from other causes of dementia using 123I-FP-CIT 
SPECT. The study found a mean sensitivity of 78% for detecting DLB and a mean 
specificity of 90% for excluding non-DLB, which was predominantly due to AD 
(McKeith et al., 2007). A revision of the DLB clinical consensus criteria has now been 
made, where a diagnosis of ‘probable DLB’ is given on the basis of one of the core 
features (fluctuations, hallucinations or parkinsonism) supported by an abnormal 123I-FP-
CIT scan (McKeith et al., 2005). Another SPECT tracer which has shown potential in the 
differential diagnosis of DLB is 123I-MIBG; a ligand used in myocardial scintigraphy that 
detects early disturbances of the sympathetic nervous system. Hanyu et al, showed that 
when using heart to mediastinum ratios, a high diagnostic accuracy was achieved 
(sensitivity 100%, specificity 92%) in distinguishing ante-mortem cases of DLB from AD 
(Hanyu et al., 2006a). However, few studies have been reported and further 
investigations are required to establish the role of 123I-MIBG SPECT in the diagnosis of 
DLB. 
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Strengths of the present study include: the relatively large populations, consensus results 
reducing individual rater bias, rigorous clinical and neuropsychological testing of 
subjects. Potential weakness was the lack of autopsy confirmed diagnoses and therefore 
the reliance on clinical diagnosis as the ‘gold standard’. Autopsy data was available for 9 
patients (2 AD, 7 DLB). 123I-FP-CIT was shown to have a sensitivity of 80% and 
specificity 100% in diagnosing DLB according to autopsy, and was largely in agreement 
with a previous 123I-FP-CIT study of autopsy confirmed DLB cases (Walker et al., 2002; 
Walker et al., 2007). There was one false negative autopsy case, i.e., DLB with a 
‘normal’ 123I-FP-CIT scan.  The patient had ‘global’ but mild parkinsonism (UPDRS III 
= 17) and there was evidence of neuronal loss in substantia nigra. Lewy body pathology 
was moderate in limbic areas and substantia nigra while mild or absent in other brain 
stem nuclei and neocortical regions. Alzheimer type pathology was severe in medial 
temporal lobe, moderately severe in lateral temporal and parietal cortex, and moderate in 
frontal and occipital lobes (Braak stage 5). The data was suggestive of ‘mixed’ pathology 
although the case was most likely at the AD end of the spectrum of DLB. 99mTc-
exametazime was diagnostically less accurate than 123I-FP-CIT in classifying autopsy 
diagnosed AD and DLB cases, although perfusion SPECT has been shown to have a role 
in distinguishing AD from vascular dementia (Hanyu et al., 1995). Much larger autopsy 
confirmed populations are required in order to reveal the true diagnostic utility of 99mTc-
exametazime and 123I-FP-CIT imaging in AD and DLB. 
 
In summary, the study compared 99mTc-exametazime with 123I-FP-CIT in the diagnosis of 
DLB from AD. Diagnostic accuracy was superior with 123I-FP-CIT compared to 99mTc-
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exametazime in accordance with clinical diagnosis. Visual inspection demonstrated that 
the pattern of cerebral perfusion is moderately shared between AD and DLB, and points 
to the challenge in separating these groups using perfusion SPECT imaging alone. Other 
tracers are now available that may offer additional diagnostic information in support of 
an accurate antemortem diagnosis of DLB. Further SPECT studies are required with large 
autopsy confirmed populations in order to reveal the true extent such tracers have on the 
differential diagnosis of DLB. 
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Table 1: Demographic and clinical characteristics of subjects. 
 
 
 
 
Control 
 
AD 
 
DLB 
 
p value 
     
n 39 36 30  
Sex (M: F) 21: 18 15: 21 18: 12 Ns 
     
Age (yrs) 75.1 ± 6.6 78.7 ± 5.5 76.0 ± 6.5 0.05 
MMSE (max. 30) 28.2 ± 1.5 17.7 ± 4.9 16.3 ± 5.4 <0.001* 
CAMCOG (max. 107) 93.9 ± 3.9 59.5 ± 15.4 60.3 ± 14.4 <0.001* 
UPDRS III (max. 108) 1.3 ± 2.0 5.6 ± 5.0 26.4 ± 14.9 <0.001** 
Disease Duration (yrs) Na 3.1 ± 1.5 2.4 ± 1.9 Ns 
     
Medications     
 Cholinesterase Inhibitors  
0 
0 
 
7 
2 
 
9 
0 
 
 Donepezil 
 Rivastigmine 
 L-Dopa 0 0 3  
     
 
Values expressed as (Mean ± 1 Standard deviation). 
 
*Con > DLB, AD; **DLB > Con, AD (ANOVA). 
 
AD= Alzheimer’s Disease; DLB= Dementia with Lewy Bodies; MMSE= Mini-Mental State Examination; 
CAMCOG= Cambridge Cognitive Examination; UPDRS III = Unified Parkinson’s Disease Rating Scale 
(motor subsection); Ns= Not significant; Na=Not applicable. 
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Table 2: Incidence of reduced uptake from consensus visual rating of 99mTc-exametazime 
and 123I-FP-CIT SPECT scans in controls, AD and DLB.  
 
 
  
Clinical Diagnosis 
 
  
Control (39) 
 
AD (36) 
 
DLB (30) 
99mTc-exametazime     
Reduced temporal uptake  8 (21%) 31 (86%) 17 (57%) 
     
Reduced occipital uptake  6 (15%) 12 (33%) 19 (63%) 
     
Reduced parietal uptake  8 (21%) 25 (69%) 24 (80%) 
     
Reduced midline parietal uptake  4 (10%) 12 (33%) 17 (57%) 
     
Consensus diagnosis = Clinical diagnosis  30 (80%) 19 (53%) 18 (60%) 
     
Complete concordance in consensus diagnosis  23 (59%) 12 (33%) 7 (23%) 
     
123I-FP-CIT     
*Reduced striatal uptake  2 (6%) 4 (12%) 22 (79%) 
    
 
*Control (n=33), AD (n=33), DLB (n=28)  
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Table 3: ROC curve visual rating results from 99mTc-exametazime scores by region and 
123I-FP-CIT in distinguishing DLB from AD. Sensitivity, specificity, positive and 
negative likelihood ratios (±LR) are presented. 
 
 
ROC Curve 
Area 
(Area ±  Standard error) 
Sensitivity† 
(%) 
Specificity† 
(%) 
 
+LR 
 
-LR 
 
99mTc-exametazime      
      
Temporal 0.65 ± 0.07§ 86.1§ 43.3§ 1.5§ 0.3§ 
Occipital 0.65 ± 0.07 63.3 66.7 1.9 0.6 
 0.64 ± 0.07* 64.3* 63.6* 1.8* 0.6* 
Parietal 0.55 ± 0.07 80.0 30.6 1.2 0.7 
Midline Parietal 0.62 ± 0.07 56.7 66.7 1.7 0.7 
      
123I-FP-CIT 0.83 ± 0.05 78.6 87.9 6.5 0.2 
      
 
*99mTc-exametazime cases with a 123I-FP-CIT scan (AD = 33, DLB = 28). 
§Direction of a positive test result is AD. Others denote positive test result as DLB. 
†Values corresponding to minimum false-negative and false-positive results. 
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Table 4: SPECT imaging characteristics of autopsy confirmed cases. 
 
Case 
 
Clinical 
Diagnosis 
 
Autopsy 
Diagnosis 
 
FPCIT 
 
99mTc-exametazime 
Diagnosis 
 
Temp 
 
Occ 
 
Par 
 
Mid 
Par 
         
1 DLB DLB Abnormal DLB R R R N 
2 AD AD Normal DLB N R R N 
3 DLB DLB Abnormal DLB R N R R 
4 DLB DLB Normal AD R N N N 
5 DLB DLB No Scan DLB N R N N 
6 AD AD Normal AD R R R R 
7 DLB DLB Abnormal AD R R R R 
8 DLB AD Normal Control N N R N 
9 DLB DLB Abnormal Control N N N N 
         
 
Key: =Visual rating diagnosis; Temp=Temporal/medial temporal; Occ=Occipital; Par=Parietal; Mid 
Par=Midline Parietal; R=Reduced uptake; N=Normal uptake. 
 
 
 
 
 
 
 
 
 
 
 
 
Differential diagnosis of AD and DLB 
 31
Figure 1. MRIcro display of the 99mTc-exametazime SPECT template in standard space. 
Schematic shows transverse and coronal views as well as colour scale used for the visual 
rating of scans. Neuroanatomical landmarks within each slice are also illustrated. 
 
 
Figure 2. Typical transverse views of normal (a) and abnormal (b) 123I-FPCIT SPECT 
scans. 
 
Figure 3. Representative axial 99mTc-exametazime SPECT scans of groups in standard 
MNI space.  (a) Control: perfusion is relatively well preserved in cortical regions. (b) 
AD: loss of uptake in temporal and medial temporal lobes (white arrows). Observe that 
occipital binding remains largely unaffected (green arrows). (c) DLB: reduced uptake in 
occipital lobe (white arrows), while temporal and medial temporal blood flow remains 
relatively unchanged (green arrows). 
 
Figure 4. ROC curves of occipital rCBF 99mTc-exametazime and 123I-FPCIT SPECT 
using visual rating in the classification of AD and DLB in accordance with clinical 
diagnosis. 
